Literature DB >> 33135188

Myocardial injury in severe and critical coronavirus disease 2019 patients.

Huiqi Guo1, Yunzhi Shen1, Ning Wu2, Xiaotian Sun2.   

Abstract

BACKGROUND AND AIM OF THE STUDY: To investigate the effect of myocardial injury on the prognosis of patients with severe or critical coronavirus disease 2019 (COVID-19).
METHODS: Between February 10, 2020 and March 31, 2020, data of severe and critical COVID-19 patients were collected and retrospectively analyzed. Admission data included age, heart rates, mean arterial pressure, and myocardial injury markers including creatine kinase isoenzyme-MB (CK-MB), myoglobin, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and interleukin-6. The endpoints included mortality, the incidence of malignant arrhythmia, and mechanical ventilation time. Univariate regression analysis, multivariate linear regression analysis, and binary logistic analysis were performed to develop the risk predictors in myocardial injury to the prognosis of severe and critical COVID-19 patients.
RESULTS: Seventy-four COVID-19 patients were included (mean age of 67.2 ± 14.6 years, male of 66.2%), including 42 severe and 32 critical cases. The mortality was 62.2% (n = 46). CK-MB (odds ratio = 5.895, p < .001, 95% confidence interval: 3.097-8.692) and interleukin-6 (odds ratio = 0.379; p = .005; 95% confidence interval: 1.051-1.769) were independent risk factors of increased mechanical ventilation time; myoglobin (odds ratio = 7.710; p = .045; 95% confidence interval: 1.051-56.571) were the independent predictor of incidence of malignant arrhythmia; age (odds ratio = 1.077; p = .009; 95% confidence interval: 1.019-1.139), myoglobin (odds ratio = 9.480; p = .032; 95% confidence interval: 1.211-78.188), and NT-proBNP (odds ratio = 4.852; p = .047; 95% confidence interval: 0.956-24.627) were the independent predictors of mortality.
CONCLUSIONS: In severe and critical COVID-19 patients, the obvious myocardial injury was observed. Increases of CK-MB, myoglobin, NT-proBNP, interleukin-6, and age were independently associated with poor prognosis including increased ventilation duration, the incidence of malignant arrhythmia, and mortality.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  coronavirus disease 2019; mortality; myocardial injury; prognosis

Year:  2020        PMID: 33135188     DOI: 10.1111/jocs.15164

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  6 in total

1.  Cardiac biomarkers and COVID-19: A systematic review and meta-analysis.

Authors:  Wen An; Ju-Seop Kang; Qiuyang Wang; Tae-Eun Kim
Journal:  J Infect Public Health       Date:  2021-07-29       Impact factor: 7.537

2.  Associations between Serum Interleukins (IL-1β, IL-2, IL-4, IL-6, IL-8, and IL-10) and Disease Severity of COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Yuanmin Chang; Mengru Bai; Qinghai You
Journal:  Biomed Res Int       Date:  2022-04-30       Impact factor: 3.246

3.  Subclinical myocardial injury, coagulopathy, and inflammation in COVID-19: A meta-analysis of 41,013 hospitalized patients.

Authors:  Oluwabunmi Ogungbe; Baridosia Kumbe; Oluwadamilola Agnes Fadodun; T Latha; Diane Meyer; Adetoun Faith Asala; Patricia M Davidson; Cheryl R Dennison Himmelfarb; Wendy S Post; Yvonne Commodore-Mensah
Journal:  Int J Cardiol Heart Vasc       Date:  2022-01-04

4.  Cardiovascular markers and COVID-19.

Authors:  El-Houcine Sebbar; Mohammed Choukri
Journal:  Mater Today Proc       Date:  2022-08-02

5.  B-Type Natriuretic Peptide Concentrations, COVID-19 Severity, and Mortality: A Systematic Review and Meta-Analysis With Meta-Regression.

Authors:  Angelo Zinellu; Salvatore Sotgia; Ciriaco Carru; Arduino A Mangoni
Journal:  Front Cardiovasc Med       Date:  2021-06-24

Review 6.  Serum CK-MB, COVID-19 severity and mortality: An updated systematic review and meta-analysis with meta-regression.

Authors:  Angelo Zinellu; Salvatore Sotgia; Alessandro G Fois; Arduino A Mangoni
Journal:  Adv Med Sci       Date:  2021-07-07       Impact factor: 3.287

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.